Daiichi Sankyo Company, Limited
4568
Peringkat dalam Saham
#729
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Harga Saham
$18.01
Kapitalisasi Pasar
$32.77B
Perubahan (1 hari)
0.14%
Perubahan (1 tahun)
-30.22%
Negara
JP
Perdagangan Daiichi Sankyo Company, Limited (4568)
Kategori
Healthcare
Rasio P/E untuk Daiichi Sankyo Company, Limited (4568)
Rasio P/E per October 2026 TTM: 21.47
Menurut laporan keuangan dan harga saham terbaru dari Daiichi Sankyo Company, Limited, rasio P/E saat ini (TTM) adalah 21.47. Pada akhir 2025, perusahaan memiliki rasio P/E sebesar 22.51.
Riwayat rasio P/E untuk Daiichi Sankyo Company, Limited dari 2001 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 21.47 | -4.61% |
| 2025 | 22.51 | -49.50% |
| 2024 | 44.58 | -47.34% |
| 2023 | 84.66 | 10.38% |
| 2022 | 76.70 | -6.85% |
| 2021 | 82.34 | 120.64% |
| 2020 | 37.32 | -2.53% |
| 2019 | 38.29 | -0.84% |
| 2018 | 38.61 | 22.65% |
| 2017 | 31.48 | 50.17% |
| 2016 | 20.96 | 403.01% |
| 2015 | 4.17 | -79.24% |
| 2014 | 20.08 | 9.51% |
| 2013 | 18.33 | -82.07% |
| 2012 | 102.24 | 534.14% |
| 2011 | 16.12 | -45.26% |
| 2010 | 29.45 | -643.67% |
| 2009 | -5.42 | -124.90% |
| 2008 | 21.76 | -35.05% |
| 2007 | 33.50 | 49.10% |
| 2006 | 22.47 | 0.07% |
| 2005 | 22.45 | 9.57% |
| 2004 | 20.49 | -2.12% |
| 2003 | 20.94 | -26.72% |
| 2002 | 28.57 | -7.80% |
| 2001 | 30.99 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 43.73 | 103.66% |
US
|
|
| 39.77 | 85.21% |
US
|
|
| 80.21 | 273.57% |
US
|
|
| 121.17 | 464.29% |
US
|
|
| 25.53 | 18.88% |
CH
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.